<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401345</url>
  </required_header>
  <id_info>
    <org_study_id>IRC/1603/019</org_study_id>
    <nct_id>NCT04401345</nct_id>
  </id_info>
  <brief_title>Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia</brief_title>
  <official_title>Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajesh Deshar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B.P. Koirala Institute of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is prospective randomised double blind study conducted in parturients planned for&#xD;
      non-elective caesarean section under spinal anaesthesia. Glycopyrrolate group will receive&#xD;
      0.2 mg of Glycopyrrolate before start of phenylephrine infusion. Control group will receive&#xD;
      0.2 ml of Normal Saline before start of phenylephrine infusion. Total amount of vasopressors&#xD;
      required i.e. ephedrine or phenylephrine will recorded in the form of phenylephrine&#xD;
      equivalent during intraoperative period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous glycopyrrolate has been investigated for its effect on haemodynamic changes after&#xD;
      spinal anesthesia for caesarean delivery. Results from previous studies are conflicting as&#xD;
      glycopyrrolate has shown to reduce, increase or had no effect on incidence of maternal&#xD;
      hypotension and/or vasopressor requirement after spinal anaesthesia. A recent meta-analysis&#xD;
      found that prophylactic glycopyrrolate does not prevent the incidence of spinal-induced&#xD;
      hypotension; however, it reduces the total vasopressor requirement during elective caesarean&#xD;
      delivery under spinal anaesthesia. Therefore, the aim of this study is to find out whether&#xD;
      the use of glycopyrrolate decreases the amount of vasopressors required to manage hypotension&#xD;
      induced by spinal anaesthesia in non-elective CS.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      After approval from Institutional Review committee of B.P. Koirala Institute of Health&#xD;
      Sciences, the trial will be registered at clinical trial.gov. Parturient planned for&#xD;
      non-elective caesarian of ASA PS grade II fulfilling the inclusion criteria will be informed&#xD;
      about the study and written consent will be obtained either in labour room or in obstetric&#xD;
      emergency ward. The eligible patients will be randomly assigned to Glycopyrrolate (GP group)&#xD;
      or normal saline (NS group). The study will be conducted in accordance with the ethical&#xD;
      principles of the 1964 Declaration of Helsinki. Before patient is shifted to the operating&#xD;
      room (OR), ranitidine 50 mg and metoclopramide 10 mg will be administered intravenously via&#xD;
      18 G cannula. In the operating table, patients will be laid supine with a wedge placed in the&#xD;
      right hip. Standard anaesthesia monitoring including 3-lead electrocardiography, heart rate&#xD;
      (HR), noninvasive blood pressure (NIBP) and pulse oximetry (Sp02) will be done. A mean value&#xD;
      of three measurements of systolic blood pressure (SBP) and HR will be recorded as baseline&#xD;
      parameters. Patency of the vein will be maintained with the infusion of Ringer's lactate&#xD;
      solution at a minimal rate.&#xD;
&#xD;
      Before the patient is placed in sitting position for SA,she will receive the study drug&#xD;
      according to the randomization. After free flow of CSF is observed, 0.5 % hyperbaric&#xD;
      bupivacaine (2.2 ml) with 10 µg fentanyl will be injected intrathecally over 30 s using a&#xD;
      25-gauge Quinke needle at the L3-4 or L4-L5 interspace. Patients will then be immediately&#xD;
      placed in supine while maintaining 15 degree left lateral tilt. Co-loading of 1000 ml ringers&#xD;
      lactate solution will be initiated at the start of spinal anaesthesia using a pressure bag&#xD;
      and it will be completed within 10 min. Immediately after the spinal injection, phenylephrine&#xD;
      infusion will be initiated at a rate of 25 µg/min and it will be titrated to maintain&#xD;
      maternal SBP within 20 % of baseline.&#xD;
&#xD;
      The sensory level of anaesthesia will be checked using loss of cold sensation. Surgery will&#xD;
      be allowed once the bilateral sensory block height at T6 is achieved. Oxygen at 40% will be&#xD;
      administered via nasal cannula at 2-4 L/min until delivery.&#xD;
&#xD;
      Hemodynamic parameters will be recorded at following time intervals: baseline, after the&#xD;
      study drug in given IV, immediately after spinal anaesthesia, every minute for first 10 min,&#xD;
      and then at 2.5 min until end of surgery. Post-spinal hypotension will be defined as SBP &lt;&#xD;
      80% of baseline reading or SBP &lt; 100 mmHg before delivery of baby. Post-delivery hypotension&#xD;
      is defined as SBP &lt; 80% of baseline reading or SBP &lt; 100 mmHg after delivery of the baby. It&#xD;
      will be treated with phenylephrine 100 µg bolus and rapid infusion of Ringer's lactate 200&#xD;
      ml. Infusion of phenylephrine will be stopped if bradycardia (HR&lt; 55/min) occurs without&#xD;
      hypotension. If bradycardia (HR&lt; 55/min) is associated with hypotension, IV ephedrine 6 mg&#xD;
      will be administered. If these measures fail and bradycardia is still persistent then an IV&#xD;
      atropine 0.5 mg will be given. If reactive hypertension (defined as SBP &gt; 120% of baseline&#xD;
      reading) occurs, the infusion of phenylephrine will be stopped and restarted only when the&#xD;
      SBP reaches the target range (SBP is within 120% of baseline SBP). The amount of ephedrine&#xD;
      used will be converted to phenylephrine equivalent based on potency of phenylephrine to&#xD;
      ephedrine as 81:1 ratio.(31)&#xD;
&#xD;
      After delivery of the baby, 2 U of oxytocin will be administered IV over 5-10 sec followed by&#xD;
      an infusion of 10 U/hr (oxytocin 20 U in 500 ml of Hartmann's solution). Phenylephrine&#xD;
      infusion will be gradually tapered after delivery of the baby keeping the SBP within the&#xD;
      target level. The total amount of intraoperative IV fluids administered and estimated blood&#xD;
      loss will be measured. Intraoperative use of other uterotonic agent or blood transfusion will&#xD;
      be recorded. The attending pediatrician will assess neonatal Apgar scores at 1 and 5 minutes&#xD;
      after delivery.&#xD;
&#xD;
      Patients will be asked to report the occurrence of intraoperative nausea and rate its&#xD;
      severity using an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea).&#xD;
      Intraoperative nausea or vomiting (IONV) will be treated with ondansetron 4 mg IV. After 5&#xD;
      min, if nausea and vomiting is still persisted, IV dexamethasone 4 mg will be administered.&#xD;
      IONV incidence and its time of occurrence from intrathecal injection (whether associated with&#xD;
      hypotension) and antiemetic needed will be recorded. Incidence of intraoperative pruritus,&#xD;
      shivering, dizziness and dry mouth will also be recorded. Grading of intraoperative shivering&#xD;
      is as follows: 0 no shivering, 1 one or more of the following: piloerection, peripheral&#xD;
      vasoconstriction, peripheral cyanosis without other cause, but without visible muscular&#xD;
      activity; 2 visible muscular activity confined to one muscle group; 3 visible muscular&#xD;
      activity in more than one muscle group; and 4 gross muscular activity involving the whole&#xD;
      body. If the shivering score is ≥3, IV meperidine 20 mg will be given.&#xD;
&#xD;
      The primary outcome will be the total amount of phenylephrine used to maintain blood pressure&#xD;
      intraoperatively. The secondary outcome measures will include incidence of maternal&#xD;
      hypotension, reactive hypertension, bradycardia, other side-effects (IONV, shivering,&#xD;
      pruritus, dry mouth,dizziness), changes in maternal SBP and heart rate and neonatal outcome&#xD;
      (Apgar scores at 1 min and 5 min, requirement of neonatal resuscitation, need for neonatal&#xD;
      ICU admission and neonatal death within 30 days).&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      Baseline data (gestational age, uterine incision to delivery time, hemodynamic parameters)&#xD;
      and outcome parameters will be collected in the paper case record form and entered in windows&#xD;
      Microsoft excel spreadsheet for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental Group (GP): In the experimental group patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated.&#xD;
Placebo Group (NS): In the placebo group patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Glycopyrrolate and normal saline will be administered as 1 ml clear fluid, and therefore, both patient and investigator will be blinded to the randomization and intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total vasopressors requirement intraoperatively</measure>
    <time_frame>immediately after spinal anaesthesia till the end of the surgery</time_frame>
    <description>Total vasopressors required to prevent hypotension during the period of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypotension</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>Hypotension is defined as systolic blood pressure &lt; 80% of baseline reading or systolic blood pressure &lt; 100 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of reactive hypertension</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>defined as systolic blood pressure &gt; 120% of baseline reading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of maternal bradycardia</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>heart rate &lt; 55/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of maternal tachycardia</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>Heart rate &gt; 100/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of nausea</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>Patients will be asked to report the occurrence of intraoperative nausea and rate its severity using an 11-point verbal rating scale (0=no nausea, 10=worst possible nausea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of vomiting</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>incidence of vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of shivering</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>Shivering will be graded as: 0 no shivering, 1 one or more of the following: piloerection, peripheral vasoconstriction, peripheral cyanosis without other cause, but without visible muscular activity; 2 visible muscular activity confined to one muscle group; 3 visible muscular activity in more than one muscle group; and 4 gross muscular activity involving the whole body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of dry mouth, intraoperative pruritus and dizziness</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>incidence of dry mouth, intraoperative pruritus and dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal heart rate and</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>to record the heart rate of the patient during surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal systolic blood pressure</measure>
    <time_frame>after spinal anaesthesia till the end of the surgery</time_frame>
    <description>to record systolic blood pressure of the patient during surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The APGAR outcome of baby</measure>
    <time_frame>at 1 and 5 min after delivery</time_frame>
    <description>APGAR score comprises of 5 criteria : a) Appearance b) Pulse Rate c) Reflex d)Muscle tone e) Respiratory Effort with each criteria of score 0,1 or 2; making total score of 10. Score 7-10 is reassuring, 4-6 moderately normal, 0-3 is low and cause for immediate resuscitative efforts</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for neonatal resuscitation</measure>
    <time_frame>immediately after delivery</time_frame>
    <description>resuscitation needed for baby</description>
  </other_outcome>
  <other_outcome>
    <measure>Admission to neonatal ICU (NICU)</measure>
    <time_frame>after delivery</time_frame>
    <description>the need for ICU admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal death</measure>
    <time_frame>within 30 days of delivery</time_frame>
    <description>if there is neonatal death or not</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Glycopyrrolate</condition>
  <condition>Post-spinal Hypotension</condition>
  <condition>Effect of Drug</condition>
  <condition>Hemodynamic Instability</condition>
  <arm_group>
    <arm_group_label>Experimental Group (GP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.2 mg (1 ml) glycopyrrolate before phenylephrine infusion is initiated at 25mcg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group(NS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive 1 ml normal saline (0.9%) before phenylephrine infusion is initiated at 25 mcg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate 0.2 MG/ML</intervention_name>
    <description>In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml</description>
    <arm_group_label>Experimental Group (GP)</arm_group_label>
    <other_name>Glycopyrronium bromide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>In this group, the patients will receive 1 ml of 0.9% normal saline</description>
    <arm_group_label>Placebo Group(NS)</arm_group_label>
    <other_name>0.9% NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-40 years&#xD;
&#xD;
          -  All parturients at term (gestational weeks ≥ 37)&#xD;
&#xD;
          -  ASA (American society of Anaesthesiologist) PS (Physical status) grade II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;40 year&#xD;
&#xD;
          -  ASA PS Grade &gt;2&#xD;
&#xD;
          -  Maternal bradycardia (baseline HR&lt; 60/min) or tachycardia (baseline HR&gt; 100/min)&#xD;
&#xD;
          -  Pregnancy induced hypertension&#xD;
&#xD;
          -  Gestational hypertension&#xD;
&#xD;
          -  Known fetal abnormalities&#xD;
&#xD;
          -  Intrauterine growth retardation (IUGR)&#xD;
&#xD;
          -  Intrauterine fetal death (IUFD)&#xD;
&#xD;
          -  Contraindications to spinal anaesthesia&#xD;
&#xD;
          -  Contraindications to glycopyrrolate&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  BMI: &gt; 30 kg/m2&#xD;
&#xD;
          -  Height: &lt;150cm&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>B.P.Koirala Institute of Health Sciences</name>
      <address>
        <city>Dharān Bāzār</city>
        <state>Province 1</state>
        <zip>56700</zip>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nepal</country>
  </location_countries>
  <reference>
    <citation>Yentis SM, Jenkins CS, Lucas DN, Barnes PK. The effect of prophylactic glycopyrrolate on maternal haemodynamics following spinal anaesthesia for elective caesarean section. Int J Obstet Anesth. 2000 Jul;9(3):156-9.</citation>
    <PMID>15321086</PMID>
  </reference>
  <reference>
    <citation>Saravanan S, Kocarev M, Wilson RC, Watkins E, Columb MO, Lyons G. Equivalent dose of ephedrine and phenylephrine in the prevention of post-spinal hypotension in Caesarean section. Br J Anaesth. 2006 Jan;96(1):95-9. Epub 2005 Nov 25.</citation>
    <PMID>16311286</PMID>
  </reference>
  <results_reference>
    <citation>Somboonviboon W, Kyokong O, Charuluxananan S, Narasethakamol A. Incidence and risk factors of hypotension and bradycardia after spinal anesthesia for cesarean section. J Med Assoc Thai. 2008 Feb;91(2):181-7.</citation>
    <PMID>18389982</PMID>
  </results_reference>
  <results_reference>
    <citation>Dyer RA, Biccard BM. Ephedrine for spinal hypotension during elective caesarean section: the final nail in the coffin? Acta Anaesthesiol Scand. 2012 Aug;56(7):807-9. doi: 10.1111/j.1399-6576.2012.02719.x.</citation>
    <PMID>22780437</PMID>
  </results_reference>
  <results_reference>
    <citation>Kinsella SM, Tuckey JP. Perioperative bradycardia and asystole: relationship to vasovagal syncope and the Bezold-Jarisch reflex. Br J Anaesth. 2001 Jun;86(6):859-68. Review.</citation>
    <PMID>11573596</PMID>
  </results_reference>
  <results_reference>
    <citation>Dobson PM, Caldicott LD, Gerrish SP, Cole JR, Channer KS. Changes in haemodynamic variables during transurethral resection of the prostate: comparison of general and spinal anaesthesia. Br J Anaesth. 1994 Mar;72(3):267-71.</citation>
    <PMID>8130043</PMID>
  </results_reference>
  <results_reference>
    <citation>Ali S, Athar M, Ahmed SM. Basics of CPB. Indian J Anaesth. 2019;49:257-62.</citation>
  </results_reference>
  <results_reference>
    <citation>Lee AJ, Landau R. Aortocaval Compression Syndrome: Time to Revisit Certain Dogmas. Anesth Analg. 2017 Dec;125(6):1975-1985. doi: 10.1213/ANE.0000000000002313. Review.</citation>
    <PMID>28759487</PMID>
  </results_reference>
  <results_reference>
    <citation>Dick WF. Anaesthesia for caesarean section (epidural and general): effects on the neonate. Eur J Obstet Gynecol Reprod Biol. 1995 May;59 Suppl:S61-7. Review.</citation>
    <PMID>7556827</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuhn JC, Hauge TH, Rosseland LA, Dahl V, Langesæter E. Hemodynamics of Phenylephrine Infusion Versus Lower Extremity Compression During Spinal Anesthesia for Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Study. Anesth Analg. 2016 Apr;122(4):1120-9. doi: 10.1213/ANE.0000000000001174.</citation>
    <PMID>26991619</PMID>
  </results_reference>
  <results_reference>
    <citation>Cyna AM, Andrew M, Emmett RS, Middleton P, Simmons SW. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD002251. Review.</citation>
    <PMID>17054153</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee AJ, Landau R, Mattingly JL, Meenan MM, Corradini B, Wang S, Goodman SR, Smiley RM. Left Lateral Table Tilt for Elective Cesarean Delivery under Spinal Anesthesia Has No Effect on Neonatal Acid-Base Status: A Randomized Controlled Trial. Anesthesiology. 2017 Aug;127(2):241-249. doi: 10.1097/ALN.0000000000001737.</citation>
    <PMID>28598894</PMID>
  </results_reference>
  <results_reference>
    <citation>Ripollés Melchor J, Espinosa Á, Martínez Hurtado E, Casans Francés R, Navarro Pérez R, Abad Gurumeta A, Calvo Vecino JM. Colloids versus crystalloids in the prevention of hypotension induced by spinal anesthesia in elective cesarean section. A systematic review and meta-analysis. Minerva Anestesiol. 2015 Sep;81(9):1019-30. Epub 2014 Dec 11. Review.</citation>
    <PMID>25501602</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercier FJ. Cesarean delivery fluid management. Curr Opin Anaesthesiol. 2012 Jun;25(3):286-91. doi: 10.1097/ACO.0b013e3283530dab. Review.</citation>
    <PMID>22459983</PMID>
  </results_reference>
  <results_reference>
    <citation>Banerjee A, Stocche RM, Angle P, Halpern SH. Preload or coload for spinal anesthesia for elective Cesarean delivery: a meta-analysis. Can J Anaesth. 2010 Jan;57(1):24-31. doi: 10.1007/s12630-009-9206-7. Epub 2009 Oct 27.</citation>
    <PMID>19859776</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharwood-Smith G, Drummond GB. Hypotension in obstetric spinal anaesthesia: a lesson from pre-eclampsia. Br J Anaesth. 2009 Mar;102(3):291-4. doi: 10.1093/bja/aep003.</citation>
    <PMID>19218369</PMID>
  </results_reference>
  <results_reference>
    <citation>Hwang J, Min S, Kim C, Gil N, Kim E, Huh J. Prophylactic glycopyrrolate reduces hypotensive responses in elderly patients during spinal anesthesia: a randomized controlled trial. Can J Anaesth. 2014 Jan;61(1):32-8. doi: 10.1007/s12630-013-0064-y. Epub 2013 Dec 18.</citation>
    <PMID>24347351</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonnell NJ, Paech MJ, Muchatuta NA, Hillyard S, Nathan EA. A randomised double-blind trial of phenylephrine and metaraminol infusions for prevention of hypotension during spinal and combined spinal-epidural anaesthesia for elective caesarean section. Anaesthesia. 2017 May;72(5):609-617. doi: 10.1111/anae.13836. Epub 2017 Mar 3.</citation>
    <PMID>28255987</PMID>
  </results_reference>
  <results_reference>
    <citation>Cardoso MM, Yamaguchi ET, Amaro AR, Mezzetti R, Torres MA. Fetal and maternal effects of bolus of phenylephrine or metaraminol during spinal anesthesia for cesarean delivery. Anesthesiology. 2005;102:A31--A31.</citation>
  </results_reference>
  <results_reference>
    <citation>Abboud TK, Read J, Miller F, Chen T, Valle R, Henriksen EH. Use of glycopyrrolate in the parturient: effect on the maternal and fetal heart and uterine activity. Obstet Gynecol. 1981 Feb;57(2):224-7.</citation>
    <PMID>7465128</PMID>
  </results_reference>
  <results_reference>
    <citation>Ali-Melkkilä T, Kaila T, Kanto J, Iisalo E. Pharmacokinetics of glycopyrronium in parturients. Anaesthesia. 1990 Aug;45(8):634-7.</citation>
    <PMID>2400072</PMID>
  </results_reference>
  <results_reference>
    <citation>Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983 Dec;38(12):1195-204.</citation>
    <PMID>6660460</PMID>
  </results_reference>
  <results_reference>
    <citation>Ure D, James KS, McNeill M, Booth JV. Glycopyrrolate reduces nausea during spinal anaesthesia for caesarean section without affecting neonatal outcome. Br J Anaesth. 1999 Feb;82(2):277-9.</citation>
    <PMID>10365009</PMID>
  </results_reference>
  <results_reference>
    <citation>Quiney NF, Murphy PG. The effect of pretreatment with glycopyrrolate on emetic and hypotensive problems during caesarean section conducted under spinal anaesthesia. Int J Obstet Anesth. 2000;9:156-9.</citation>
  </results_reference>
  <results_reference>
    <citation>Chamchad D, Horrow JC, Nakhamchik L, Sauter J, Roberts N, Aronzon B, Gerson A, Medved M. Prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia for Cesarean section: a randomized, double-blinded, placebo-controlled prospective trial with heart rate variability correlation. J Clin Anesth. 2011 Aug;23(5):361-6. doi: 10.1016/j.jclinane.2010.12.008. Epub 2011 May 31.</citation>
    <PMID>21632228</PMID>
  </results_reference>
  <results_reference>
    <citation>Yoon HJ, Cho HJ, Lee IH, Jee YS, Kim SM. Comparison of hemodynamic changes between phenylephrine and combined phenylephrine and glycopyrrolate groups after spinal anesthesia for cesarean delivery. Korean J Anesthesiol. 2012 Jan;62(1):35-9. doi: 10.4097/kjae.2012.62.1.35. Epub 2012 Jan 25.</citation>
    <PMID>22323952</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel SD, Habib AS, Phillips S, Carvalho B, Sultan P. The Effect of Glycopyrrolate on the Incidence of Hypotension and Vasopressor Requirement During Spinal Anesthesia for Cesarean Delivery: A Meta-analysis. Anesth Analg. 2018 Feb;126(2):552-558. doi: 10.1213/ANE.0000000000002274.</citation>
    <PMID>28704246</PMID>
  </results_reference>
  <results_reference>
    <citation>Allen TK, George RB, White WD, Muir HA, Habib AS. A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. Anesth Analg. 2010 Nov;111(5):1221-9. doi: 10.1213/ANE.0b013e3181e1db21. Epub 2010 May 21. Erratum in: Anesth Analg. 2011 Oct;113(4):800.</citation>
    <PMID>20495139</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Mao M, Liu S, Xu S, Yang J. A Comparative Study of Bolus Norepinephrine, Phenylephrine, and Ephedrine for the Treatment of Maternal Hypotension in Parturients with Preeclampsia During Cesarean Delivery Under Spinal Anesthesia. Med Sci Monit. 2019 Feb 9;25:1093-1101. doi: 10.12659/MSM.914143.</citation>
    <PMID>30738019</PMID>
  </results_reference>
  <results_reference>
    <citation>Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol Appl Pharmacol. 2019 May 1;370:154-169. doi: 10.1016/j.taap.2019.03.016. Epub 2019 Mar 21. Review.</citation>
    <PMID>30905688</PMID>
  </results_reference>
  <results_reference>
    <citation>Bruntion L (ed), Chabner B (ed), Knollman B (ed). Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: The McGraw Hill Companies; 2011.</citation>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>B.P. Koirala Institute of Health Sciences</investigator_affiliation>
    <investigator_full_name>Rajesh Deshar</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>caesarean section</keyword>
  <keyword>hypotension</keyword>
  <keyword>spinal anaesthesia</keyword>
  <keyword>glycopyrrolate</keyword>
  <keyword>post-spinal anaesthesia</keyword>
  <keyword>vasopressors</keyword>
  <keyword>non-elective caesarean section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

